Characteristics of human immunodeficiency virus-1 infected children receiving Highly active antiretroviral therapy: a cross-sectional study

被引:1
|
作者
Badillo, K. [1 ]
Prieto, L. [1 ]
Toledano, M. [1 ]
Guillen, S. [1 ]
Alvarez, A. [1 ]
Garcia Bermejo, I. [1 ]
Ramos Amador, J. T. [1 ]
机构
[1] Hosp Univ Getafe, Serv Pediat, Madrid, Spain
来源
ANALES DE PEDIATRIA | 2012年 / 76卷 / 06期
关键词
Highly active antiretroviral therapy; Human immunodeficiency virus infected children; Immune control; Metabolic toxicity; Virological control; HIV-INFECTION; TRANSMISSION; SURVIVAL;
D O I
10.1016/j.anpedi.2011.12.005
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Introduction: Since 1996, when HAART became available, there has been a change in the course of HIV-infection, leading it to become a chronic disease. Our aim was to describe the characteristics of the children followed up in our hospital. Patients and methods: A cross-sectional study was conducted on 32 HIV-infected children followed up until December-2010, at the University-Hospital de Getafe. Clinical and laboratory information from the last visit was collected for the evaluation of patients. Results: Thirty-two children with HIV-1 were evaluated, 29 infected through vertical-transmission. The median age was 14 years. According to the CDC classification, 56% (18/32) of children were in category A, 28% (9/32) B and 16% (5/32) C. Immunological class was 3 in 75% of children, class 2 in 9% and class 1 in 16%. The median nadir of CD4 was 337 cells/ml (12%). The median current CD4 was 749 (31%). Only one adolescent had a CD4% below 200 cells/ml due to lack of adherence. Twenty-eight patients (87%) were receiving HAART, and 4 patients were off antiretroviral treatment. Among the patients treated, 26 (93%) had viral loads <200copies/ml. The median viral-load was <20 copies/ml. Median time on antiretroviral treatment was 10 years. The combination more frequently used was two nucleoside reverse transcriptase inhibitors (NRTI) and one protease inhibitor (PI), that was given to 15 patients (47%), followed by 2 NRTI, and one non-nucleoside reverse transcriptase inhibitor (NNRTI) in 8 patients (29%). Two children received rescue therapy including raltegravir, one with tipranavir and the other with darunavir. A total of 12 patients (43%) received medication once a day, 7 of them with fixed-dose combinations in a single tablet (25%). There were metabolic complications, including hyperlipidaemia or lipodystrophy were observed in 17 children (53%). Conclusions: Most of our patients are receiving HAART, with good virological and immunological control. The prevalence of metabolic abnormalities was high. Strategies to improve adherence and decrease toxicities are needed in perinatally-acquired HIV-infected children. (C) 2011 Asociacion Espanola de Pediatria. Published by Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码:317 / 323
页数:7
相关论文
共 50 条
  • [1] Growth of human immunodeficiency virus-infected children receiving highly active antiretroviral therapy
    Nachman, SA
    Lindsey, JC
    Moye, J
    Stanley, KE
    Johnson, GM
    Krogstad, PA
    Wiznia, AA
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2005, 24 (04) : 352 - 357
  • [2] Immune reconstitution in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy: a cohort study
    Johnston, AM
    Valentine, ME
    Ottinger, J
    Baydo, R
    Gryszowka, V
    Vavro, C
    Weinhold, K
    Clair, MS
    McKinney, RE
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2001, 20 (10) : 941 - 946
  • [3] Small-airway disease and its reversibility in human immunodeficiency virus-infected children on highly active antiretroviral therapy: A cross-sectional study in an African setting
    Ayuk, Adaeze C.
    Ndukwu, Chizalu, I
    Uwaezuoke, Samuel N.
    [J]. ANNALS OF THORACIC MEDICINE, 2021, 16 (03) : 253 - 259
  • [4] Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1
    Watson, DC
    Farley, JJ
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1999, 18 (08) : 682 - 689
  • [5] Xanthomas and hyperlipidemia in a human immunodeficiency virus-infected child receiving highly active antiretroviral therapy
    Babl, FE
    Regan, AM
    Pelton, SI
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2002, 21 (03) : 259 - 260
  • [6] Physical Fitness in Children Infected with the Human Immunodeficiency Virus: Associations with Highly Active Antiretroviral Therapy
    Somarriba, Gabriel
    Lopez-Mitnik, Gabriela
    Ludwig, David A.
    Neri, Daniela
    Schaefer, Natasha
    Lipshultz, Steven E.
    Scott, Gwendolyn B.
    Miller, Tracie L.
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2013, 29 (01) : 112 - 120
  • [7] Oral manifestations in human immunodeficiency virus infected children in highly active antiretroviral therapy era
    Pinheiro, Raquel dos Santos
    Franca, Talita Tenorio
    Beder Ribeiro, Camila Maria
    Leao, Jair Carneiro
    Ribeiro de Souza, Ivete Pomarico
    Castro, Gloria Fernanda
    [J]. JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2009, 38 (08) : 613 - 622
  • [8] Effect of Antiretroviral Therapy on Circulating Lipid Levels in Human Immunodeficiency Virus Infected Patients: A Cross-sectional Study
    Devaki, R. N.
    Lad, Hasit Kumar D.
    Maheshchandra, Rana Neetaben
    Chandrika, N.
    [J]. JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2022, 16 (12) : BC06 - BC09
  • [9] Detection of lipoatrophy in human immunodeficiency virus-1-infected children treated with highly active antiretroviral therapy
    Hartman, Karin
    Verweel, Gwenda
    de Groot, Ronald
    Hartwig, Nico G.
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2006, 25 (05) : 427 - 431
  • [10] Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection
    Samaras, Katherine
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 61 (02) : 238 - 245